HC Wainwright Weighs in on Evolus’ Q4 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS) – Investment analysts at HC Wainwright reduced their Q4 2025 earnings per share (EPS) estimates for Evolus in a research note issued on Tuesday, February 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share.

Evolus (NASDAQ:EOLS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million.

EOLS has been the subject of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Mizuho set a $15.00 price objective on shares of Evolus in a research report on Wednesday. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Stifel Nicolaus cut their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Evolus currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Evolus Trading Down 3.9%

Shares of NASDAQ EOLS opened at $4.41 on Wednesday. The stock has a 50 day moving average of $6.06 and a 200-day moving average of $6.73. The company has a market capitalization of $285.86 million, a P/E ratio of -4.79 and a beta of 1.11. Evolus has a 12 month low of $4.41 and a 12 month high of $17.12.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently modified their holdings of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after purchasing an additional 1,838 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after buying an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Evolus in the first quarter valued at approximately $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Evolus by 36.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after acquiring an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in Evolus by 484.8% during the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after acquiring an additional 57,987 shares during the period. Institutional investors own 90.69% of the company’s stock.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.